A storied Chinese pharma partner of Bristol Myers, Amgen — and avid biotech supporter — plots HK IPO

Sim­cere isn’t one of the group of pre-rev­enue biotechs tak­ing ad­van­tage of Hong Kong’s 2-year-old new rules that opened up the stock ex­change.

Read more: https://bit.ly/37q4NmO